Analysis of treatments used in infections caused by Gram-positive multiresistant cocci in critically ill patients admitted to the ICU;Análisis de los tratamientos utilizados en las infecciones por cocos grampositivos multirresistentes en pacientes críticos ingresados en UCI

Revista Espanola de Quimioterapia

Volumn 25, Issue 1, 2012, Pages 65-73

  Álvarez Lerma, Francisco ^a   Martínez, Mercedes Palomar ^b   Astigarraga, Pedro Olaechea ^c   Ordeñana, Josu Insausti ^d   Pueyo, María Jesús López ^e   Arnillas, María Pilar Gracia ^a   Costa, Ricardo Gimeno ^f   Betolaza, Iratxe Seijas ^g  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL DE GALDAKAO   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

Author keywords

Daptomycin; ENVIN HELICS registry; Gram positive multiresistant cocci; ICU; Linezolid; Teicoplanin; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DRUG ACTIVITY; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PROPHYLAXIS; REGISTER;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CRITICAL ILLNESS; DAPTOMYCIN; DRUG PRESCRIPTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; TEICOPLANIN; VANCOMYCIN;

EID: 84859635621     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). Grupo de Trabajo de Enfermedades Infecciosas. Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-HELICS). Informes de los años 2008, 2009 y 2010. En: http://hws.vhebron.net/envin-helics/.(Ultima visita, octubre 2011).
2. Malacarne P, Boccalatte D, Acquarolo A, Agostini F, Anghileri A, Giardino M, et al. Epidemiology of nosocomial infection in 125 Italian intensive care units. Minerva Anestesiol 2010; 76:13-23.
3. Alvarez Lerma F, Palomar M, Insausti J, Olaechea P, Cerdá E, Sánchez Godoy J, De la Torre MV; Grupo de Estudio Nacional de Vigilancia de Infección Nosocomial en UCI. Infecciones nosocomiales por Staphylococcus aureus en pacientes críticos ingresados en unidades de cuidados intensivos. Med Clin (Barc) 2006; 126:641-646.
4. Olaechea PM, Alvarez-Lerma F, Palomar M, Insausti J, López-Pueyo MJ, Martínez-Pellús A, Cantón ML; Grupo ENVIN-HELICS. Impacto de la bacteriemia primaria y relacionada con catéter intravascular causada por Staphylococcus coagulasa negative en pacientes críticos. Med Intensiva 2011; 35:217-225.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-292.
6. Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B, Miró JM, et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin 2009; 27:105-115.
7. Mensa J, Barberán J, Llinares P, Picazo J, Bouza E, Alvarez-Lerma F, et al. Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus. Rev Esp Quimioter 2008; 21:234-258.
8. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61:525-551.
9. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
10. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-2144.
12. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 123:1143-1149.
13. Knaus WA, Wagner DP, Draper EA, Zimmerman JE. APACHE II: a severity of disease classification system; Crit Care Med 1985; 13: 818-829.
14. Le Gall JR, Lemeshow S, Saunier F. A new simplified acute psysiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2.957-963.
15. Erlandsson M, Burman LG, Cars O, Gill H, Nilsson LE, Walther SM, Hanberger H; Strama-Icu Study Group. Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. Scand J Infect Dis 2007; 39:63-69.
16. Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30:1089-1096.
17. Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection 2003; 31:208-15.
18. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999; 29:245-52.
19. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-485.
20. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillinresistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2402.
21. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-3320.
22. Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, Moore CL, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356-1362.
23. Huh JW, Lim CM, Koh Y, Kim SH, Choi SH, Kim YS, et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011; 37:639-647.